Advertisement
Advertisement
TARS
Tarsus Pharmaceuticals, Inc. Common Stock
65.33
USDSponsored
+0.81
+1.26%
Apr 22, 11:10 UTC -4
Open
TARS Earnings Reports
Positive Surprise Ratio
TARS beat 15 of 22 last estimates.
68%
Next Report
Date of Next Report
May 12, 2026
Estimate for Q1 26 (Revenue/ EPS)
$155.74M
/-$0.31
Implied change from Q4 25 (Revenue/ EPS)
+2.69%
/+55.00%
Implied change from Q1 25 (Revenue/ EPS)
+98.82%
/-51.56%
Tarsus Pharmaceuticals, Inc. Common Stock earnings per share and revenue
On Feb 23, 2026, TARS reported earnings of -0.20 USD per share (EPS) for Q4 25, missing the estimate of -0.09 USD, resulting in a -106.19% surprise. Revenue reached 151.67 million, compared to an expected 147.46 million, with a 2.86% difference. The market reacted with a +7.79% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 7 analysts forecast an EPS of -0.31 USD, with revenue projected to reach 155.74 million USD, implying an increase of 55.00% EPS, and increase of 2.69% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Nurix Therapeutics, Inc. Common stock
Report Date
Apr 08, 2026 For Q1 26
Estimate
-$0.76
Actual
-$0.79
Surprise
-2.68%
KALA BIO, Inc. Common Stock
Report Date
Apr 15, 2026 For Q4 25
Estimate
-$1.46
Actual
-$0.67
Surprise
+54.38%
Scilex Holding Company Common Stock
Report Date
Apr 10, 2026 For Q4 25
Estimate
-$0.47
Actual
-$2.21
Surprise
-360.99%
Lexaria Bioscience Corp. Common Stock
Report Date
Apr 13, 2026 For Q2 26
Estimate
-$0.09
Actual
-$0.06
Surprise
+38.08%
Quince Therapeutics, Inc. Common Stock
Report Date
Apr 10, 2026 For Q4 25
Estimate
-$1.92
Actual
-$7.10
Surprise
-268.68%
GeoVax Labs, Inc. New
Report Date
Apr 15, 2026 For Q4 25
Estimate
-$6.29
Actual
$0.00
Surprise
+99.92%
FAQ
What were Tarsus Pharmaceuticals, Inc. Common Stock's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Tarsus Pharmaceuticals, Inc. Common Stock reported EPS of -$0.20, missing estimates by -106.19%, and revenue of $151.67M, 2.86% above expectations.
How did the market react to Tarsus Pharmaceuticals, Inc. Common Stock's Q4 2025 earnings?
The stock price moved up 7.79%, changed from $69.59 before the earnings release to $75.01 the day after.
When is Tarsus Pharmaceuticals, Inc. Common Stock expected to report next?
The next earning report is scheduled for May 12, 2026.
What are the forecasts for Tarsus Pharmaceuticals, Inc. Common Stock's next earnings report?
Based on 7
analysts, Tarsus Pharmaceuticals, Inc. Common Stock is expected to report EPS of -$0.31 and revenue of $155.74M for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement